AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21448128 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) measured by accelerometers
Number of subjects: 217
Study 21448128 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous Physical Activity
Number of subjects: 217
Study 21448128 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 217
Study 21448128 — intervention group
Group type: COMPARATOR
Intervention: Baseline motor skills, aerobic fitness or %body fat
Number of subjects: 217
Study 21448355 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID consumption
Number of subjects: 54
Study 21448355 — intervention group
Group type: COMPARATOR
Intervention: Non-users of NSAIDs
Number of subjects: 54
Study 21448937 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet Energy Density Score (DEDS)
Number of subjects: 19
Study 21448937 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet Variety Score (DVS)
Number of subjects: 19
Study 21450159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine, acute course, dosage and duration not specified
Number of subjects: 0
Study 21450208 — intervention group
Group type: EXPERIMENTAL
Intervention: First tertile of PWV
Number of subjects: 873
Study 21450208 — intervention group
Group type: EXPERIMENTAL
Intervention: Second tertile of PWV
Number of subjects: 873
Study 21450208 — intervention group
Group type: EXPERIMENTAL
Intervention: Third tertile of PWV
Number of subjects: 873
Study 21450573 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol at maximal tolerated dose
Number of subjects: 30
Study 21450900 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (IM) frontline treatment
Number of subjects: 559
Study 21450987 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 956
Study 21450987 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 956
Study 21450987 — intervention group
Group type: COMPARATOR
Intervention: Exenatide 10 μg
Number of subjects: 956
Study 21450987 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from exenatide to liraglutide
Number of subjects: 956
Study 21454450 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Number of subjects: 0
Study 21454450 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressive agents, rituximab, autologous cytotoxic T cells, cytotoxic chemotherapy
Number of subjects: 0
Study 21454794 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial tRNA(Ile) 4263A>G mutation
Number of subjects: 106
Study 21454794 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial dysfunction due to 4263A>G mutation
Number of subjects: 106
Study 21454813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dantrolene 1.25 mg/kg
Number of subjects: 10
Study 21454813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dantrolene 2.5 mg/kg
Number of subjects: 10
Study 21454813 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study 21455550 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg BIW for 12 weeks followed by 50 mg OW for 12 weeks
Number of subjects: 10
Study 21455908 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency tourniquet use in prehospital settings (671 limbs, 70%)
Number of subjects: 728
Study 21455908 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency tourniquet use in hospital settings (104 limbs, 11%)
Number of subjects: 728
Study 21455908 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency tourniquet use in both prehospital and hospital settings (169 limbs, 18%)
Number of subjects: 728
Study 21455908 — intervention group
Group type: EXPERIMENTAL
Intervention: Situations indicating tourniquet use (bleeding from multiple sites other than limbs, hospital mass casualty situations)
Number of subjects: 728
Study 21457513 — intervention group
Group type: EXPERIMENTAL
Intervention: sVEGFR-1
Number of subjects: 101
Study 21457513 — intervention group
Group type: EXPERIMENTAL
Intervention: uPA
Number of subjects: 101
Study 21457513 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF
Number of subjects: 101
Study 21458098 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin to homeostasis model assessment of insulin resistance (A/H ratio)
Number of subjects: 0
Study 21458303 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation (CRT)
Number of subjects: 96
Study 21458777 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated Late-Life Function and Disability Instrument (LL-FDI)
Number of subjects: 179
Study 21458812 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention in rural Nepal (exact details of intervention not specified)
Number of subjects: 24531
Study 21458812 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (observational data)
Number of subjects: 24531
Study 21458906 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 21459588 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron neutron capture therapy (BNCT) combined with fractionated X-ray irradiation and temozolomide.
Number of subjects: 0
Study 21459588 — intervention group
Group type: COMPARATOR
Intervention: Boron neutron capture therapy (BNCT)
Number of subjects: 0
Study 21459796 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK461364 administered intravenously at 300 mg (schedule A)
Number of subjects: 40
Study 21459796 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK461364 administered intravenously at 225 mg (schedule A)
Number of subjects: 40
Study 21459796 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK461364 administered intravenously at 100 mg (schedule B)
Number of subjects: 40
Study 21459796 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK461364 administered intravenously (both schedules)
Number of subjects: 40
Study 21459796 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK461364 at 225 mg (schedule A)
Number of subjects: 40
Study 21459796 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK461364 (both schedules)
Number of subjects: 40
Study 21463526 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable risperidone long-acting therapy (RLAT)
Number of subjects: 3069
Study 21463793 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal stenting during neoadjuvant therapy
Number of subjects: 32
Study 21463817 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission estradiol (E(2))
Number of subjects: 1408
Study 21463817 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent estradiol (E(2))
Number of subjects: 1408
Study 21463817 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in estradiol (E(2))
Number of subjects: 1408
Study 21463817 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression model performance
Number of subjects: 1408
Study 21464053 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use
Number of subjects: 15177
Study 21464053 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker use
Number of subjects: 15177
Study 21464053 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy for atrial fibrillation
Number of subjects: 15177
Study 21464053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 15177
Study 21464053 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillators
Number of subjects: 15177
Study 21464053 — intervention group
Group type: EXPERIMENTAL
Intervention: HF education for eligible patients
Number of subjects: 15177
Study 21464053 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone antagonist use
Number of subjects: 15177
Study 21464053 — intervention group
Group type: EXPERIMENTAL
Intervention: All-or-none care summary measure
Number of subjects: 15177
Study 21464053 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite care summary measure
Number of subjects: 15177
Study 21464155 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant imatinib after June 2007
Number of subjects: 882
Study 21464155 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant imatinib before June 2007
Number of subjects: 882
Study 21464155 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall imatinib treatment
Number of subjects: 882
Study 21464155 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sunitinib treatment
Number of subjects: 882
Study 21464155 — intervention group
Group type: COMPARATOR
Intervention: Imatinib utilization in 2006
Number of subjects: 882
Study 21464155 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib utilization in 2006
Number of subjects: 882
Study 21464155 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib utilization in 2009
Number of subjects: 882
Study 21464155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib utilization in 2009
Number of subjects: 882
Study 21464430 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPD) up to 80 mg/day
Number of subjects: 23
Study 21464430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 21464430 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPD)
Number of subjects: 23
Study 21465636 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral imatinib at 340 mg/m²
Number of subjects: 51
Study 21467128 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg/day
Number of subjects: 10
Study 21467128 — intervention group
Group type: COMPARATOR
Intervention: Control (no change in medication)
Number of subjects: 10
Study 21467178 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma cohort (n = 87)
Number of subjects: 309
Study 21467178 — intervention group
Group type: COMPARATOR
Intervention: Cataract cohort (n = 38)
Number of subjects: 309
Study 21467178 — intervention group
Group type: EXPERIMENTAL
Intervention: Forecasting method
Number of subjects: 309
Study 21467546 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 75
Study 21468300 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal triple-antiretroviral regimen (zidovudine, lamivudine, and either nevirapine or nelfinavir) from 34-36 weeks' gestation to 6 months postpartum
Number of subjects: 487
Study 21468300 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal triple-antiretroviral regimen
Number of subjects: 487
Study 21468304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir-based regimen
Number of subjects: 32
Study 21468304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine-based regimen
Number of subjects: 32
Study 21468304 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine
Number of subjects: 32
Study 21468304 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 32
Study 21468309 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 400 mg dose of albendazole (ALB)
Number of subjects: 7
Study 21470010 — intervention group
Group type: EXPERIMENTAL
Intervention: XRX-001 vaccine (4.8 μg antigen)
Number of subjects: 60
Study 21470010 — intervention group
Group type: EXPERIMENTAL
Intervention: XRX-001 vaccine (0.48 μg antigen)
Number of subjects: 60
Study 21470010 — intervention group
Group type: EXPERIMENTAL
Intervention: XRX-001 vaccine (both dosages)
Number of subjects: 60
Study 21470010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21470045 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine (ETR) 200 mg twice daily
Number of subjects: 28
Study 21470813 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 1402
Study 21471286 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (500 mg for 5 days before surgery and continued postoperatively until recurrence)
Number of subjects: 22
Study 21471286 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (12 patients)
Number of subjects: 22
Study 21471568 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet for 12 months
Number of subjects: 22
Study 21471568 — intervention group
Group type: COMPARATOR
Intervention: Presence of intestinal anti-TG2 antibodies
Number of subjects: 22
Study 21471568 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal fatty acid-binding protein (I-FABP)
Number of subjects: 22
Study 21473790 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat in combination with pelvic palliative radiotherapy
Number of subjects: 14
Study 21473790 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat at the maximum-tolerated dose
Number of subjects: 14
Study 21473790 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 14
Study 21474353 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose glyceryl triacetate (GTA) at 4.5 g/kg/d for 4.5 and 6 months respectively
Number of subjects: 2
Study 21474353 — intervention group
Group type: COMPARATOR
Intervention: Low dose glyceryl triacetate (GTA) at up to 0.25 g/kg/d
Number of subjects: 2
Study 21474571 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Bronchitis (CB+)
Number of subjects: 1061
Study 21474664 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG® parameters pre-CD
Number of subjects: 52
Study 21474664 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG® parameters post-CD
Number of subjects: 52
Study 21474786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 200 mg twice daily with food
Number of subjects: 56
Study 21474786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 300 mg twice daily
Number of subjects: 56
Study 21474786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 200 mg twice daily
Number of subjects: 56
Study 21474786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU)
Number of subjects: 56
Study 21474799 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator (reperfusion)
Number of subjects: 111
Study 21474799 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no reperfusion)
Number of subjects: 111
Study 21474799 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI analysis
Number of subjects: 111
Study 21475009 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion (BPD)
Number of subjects: 30
Study 21475009 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (Control)
Number of subjects: 30
Study 21475026 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Kasai procedure
Number of subjects: 40
Study 21475026 — intervention group
Group type: COMPARATOR
Intervention: Conventional Kasai procedure
Number of subjects: 40
Study 21475692 — intervention group
Group type: EXPERIMENTAL
Intervention: High-caloric (600 kcal) high-protein (20 g) oral nutritional supplement
Number of subjects: 29
Study 21476613 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg twice daily)
Number of subjects: 31
Study 21477202 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d
Number of subjects: 26
Study 21477202 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d
Number of subjects: 26
Study 21477202 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin overall effect
Number of subjects: 26
Study 21478218 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg) administered as two intravenous infusions 15 days apart
Number of subjects: 10
Study 21478385 — intervention group
Group type: EXPERIMENTAL
Intervention: High on-clopidogrel platelet reactivity (HCPR)
Number of subjects: 921
Study 21478385 — intervention group
Group type: EXPERIMENTAL
Intervention: High on-aspirin platelet reactivity (HAPR)
Number of subjects: 921
Study 21478385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual high on-treatment platelet reactivity (DAPR)
Number of subjects: 921
Study 21478385 — intervention group
Group type: COMPARATOR
Intervention: No high on-treatment platelet reactivity
Number of subjects: 921
Study 21478385 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPR (VerifyNow system)
Number of subjects: 921
Study 21478385 — intervention group
Group type: COMPARATOR
Intervention: No high on-treatment platelet reactivity (VerifyNow system)
Number of subjects: 921
Study 21478502 — intervention group
Group type: EXPERIMENTAL
Intervention: Copenhagen Hip and Groin Outcome Score (HAGOS)
Number of subjects: 101
Study 21478667 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0
Study 21478667 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 0
Study 21478667 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib and Nilotinib
Number of subjects: 0
Study 21480191 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.6 mg doses) with CYP3A4/P-glycoprotein inhibitors
Number of subjects: 7
Study 21480191 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.6 mg doses) with azithromycin
Number of subjects: 7
Study 21480191 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.6 mg doses) with other CYP3A4/P-glycoprotein inhibitors
Number of subjects: 7
Study 21480819 — intervention group
Group type: EXPERIMENTAL
Intervention: cART
Number of subjects: 670
Study 21480935 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care management for NVUGIB
Number of subjects: 2660
Study 21481243 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP) 234 mg
Number of subjects: 312
Study 21481243 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP) 156 mg
Number of subjects: 312
Study 21481243 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP) 39 mg
Number of subjects: 312
Study 21481243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 21481385 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 0
Study 21481577 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulse oscillometry (IOS) in COPD patients
Number of subjects: 233
Study 21481577 — intervention group
Group type: COMPARATOR
Intervention: Impulse oscillometry (IOS) in healthy non-smokers
Number of subjects: 233
Study 21481640 — intervention group
Group type: EXPERIMENTAL
Intervention: Florbetaben (¹⁸F) PET
Number of subjects: 150
Study 21481713 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 89
Study 21481713 — intervention group
Group type: EXPERIMENTAL
Intervention: Total carbohydrate intake
Number of subjects: 89
Study 21481713 — intervention group
Group type: EXPERIMENTAL
Intervention: Added sugar intake
Number of subjects: 89
Study 21481713 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic load
Number of subjects: 89
Study 21482186 — intervention group
Group type: EXPERIMENTAL
Intervention: R-miniCHOP (375 mg/m² rituximab, 400 mg/m² cyclophosphamide, 25 mg/m² doxorubicin, 1 mg vincristine, 40 mg/m² prednisone)
Number of subjects: 150
Study 21482186 — intervention group
Group type: EXPERIMENTAL
Intervention: R-miniCHOP
Number of subjects: 150
Study 21482862 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin plus valacyclovir hydrochloride (1000 mg of valacyclovir 3 times a day for 7 days plus gabapentin starting at 300 mg/d, titrated up to 3600 mg/d).
Number of subjects: 133
Study 21484766 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) dosage escalation from 200 mg to 400 mg every other week
Number of subjects: 0
Study 21484766 — intervention group
Group type: COMPARATOR
Intervention: Stable dosage of Certolizumab pegol (CZP) at 400 mg every other week
Number of subjects: 0
Study 21486866 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib combined with rituximab and dexamethasone
Number of subjects: 16
Study 21487108 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose zidovudine (600 mg orally every 6 hours) and valganciclovir (900 mg orally every 12 hours)
Number of subjects: 14
Study 21487288 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m² on days 1 and 8) and Cisplatin (75 mg/m² on day 1 of each cycle) for three 21-day cycles
Number of subjects: 52
Study 21487288 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin
Number of subjects: 52
Study 21488082 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV treatment eligibility for Black patients
Number of subjects: 4469
Study 21488082 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for treatment ineligibility
Number of subjects: 4469
Study 21488082 — intervention group
Group type: COMPARATOR
Intervention: Treatment completion evaluations
Number of subjects: 4469
Study 21488765 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic ex vivo lung perfusion (EVLP) for 4 hours
Number of subjects: 23
Study 21488765 — intervention group
Group type: COMPARATOR
Intervention: Control group (transplanted without EVLP)
Number of subjects: 23
Study 21489579 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year lifestyle intervention in 80 obese children
Number of subjects: 120
Study 21489579 — intervention group
Group type: COMPARATOR
Intervention: 1-year follow-up in 41 children with increase of SDS-BMI
Number of subjects: 120
Study 21489579 — intervention group
Group type: COMPARATOR
Intervention: Comparison of apelin levels between obese and lean children
Number of subjects: 120
Study 21489874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel-node biopsy with cervical dual injection (technetium and patent blue)
Number of subjects: 133
Study 21490076 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 11686
Study 21490142 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol intake from diet
Number of subjects: 4942
Study 21490142 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycinnamic acid esters and proanthocyanidins
Number of subjects: 4942
Study 21490142 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonalcoholic beverages and fruit
Number of subjects: 4942
Study 21491290 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C infection
Number of subjects: 97
Study 21492424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound comet-tail sign
Number of subjects: 218
Study 21492424 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide (NT-proBNP) with cutoff point 1,000 pg/mL
Number of subjects: 218
Study 21492424 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Boston criteria
Number of subjects: 218